Speaker Profile

M.D., Chief Medical Officer, Mirati Therapeutics

Biography
Alan is Chief Medical Officer at Mirati Therapeutics. Prior to Mirati, Alan was the president, head of global development, oncology, at Zai Lab. Prior to joining Zai Lab, he was the SVP and global head of late-stage oncology at Genentech, a member of the Roche Group. During his tenure at Genentech/Roche, he led the teams responsible for the global development and regulatory approval of several innovative medicines, most recently Tecentriq®. Prior to joining Genentech/Roche, Alan served as professor and chief of hematology/oncology at Oregon Health and Science University. Previously, he served on the faculties of the medical schools of Indiana University and Vanderbilt University. Alan holds a Doctor of Medicine degree from Rush Medical College. He completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center. He has over 300 publications, including articles, reviews, abstracts and book chapters.


 Session Abstract – PMWC 2023 Silicon Valley

Track 4 - January 26 9.00 A.M.-4.30 P.M.


Track Chair: Cindy Perettie, Roche

  • PMWC 2023 Award Ceremony
    - Luis Alberto Diaz Jr., MSK
    - Razelle Kurzrock, Medical College of Wisconsin
  • Non-invasive Liquid Biopsy Techniques (PANEL)
    Chair: Razelle Kurzrock, Medical College of Wisconsin
    - Apostolia Tsimberidou, MD Anderson
    - Mandana Kamgar, MD Medical College of Wisconsin
    - Mina Nikanjam, UCSD
    - Ash Alizadeh, Stanford University
  • Liquid Biopsy Challenges and Limitations (PANEL)
    Chair: Victor Lin, Mary Bird Perkins
    - Luis Alberto Diaz Jr., MSK
    - Maximilian Diehn, Stanford
    - Dana Dilbeck, Agilent
    - Emma Shtivelman, Cancer Commons
  • Liquid Biopsy in Clinical Trials: Learnings and COVID Experience (PANEL)
    Chair: Cindy Perettie, Roche Diagnostics
    - Eric Peters, Genenetch
    - Andrew Mckenzie, Sarah Cannon
    - Yang Pan, Gilead
    - Alan Sandler, Mirati Therapeutics
  • Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing
    Chair: Tom Beer, Exact Sceinces
  • Liquid Biopsy for Early Cancer Detection (PANEL)
    Chair: Priti Hegde, Foundation Medicine
    - Daniel Kim, UCSC
    - Mike Nolan, Freenome
    - Jeffrey Venstrom, Grail Bio
    - Kathryn Phillips, UCSF
    - Lon Castle, eviCore healthcare
    - Tom Beer, Exact Sciences
  • Liquid Biopsy for Minimal Residual Disease (PANEL)
    Chair: Minetta Liu, Natera
    - Peter Bach, Delfi diagnostics
    - Laura Vantveer, UCSF
    - Susan Bobulsky, Adaptive
    - Joshua Cohen, Johns Hopkins
  • PMWC Showcase
    - Harmeet Dhani, Biological Dynamics
    - Varsha Rao, Claret Bio
  • PMWC NCI Showcase
    - Xianghong Jasmine Zhou, EarlyDiagnostics